Replies to post #41376 on Biotech Values

[swampboots]

This news seems very unlikely, from my long association with this stock (NYMOX). Yet, has the words "clinical trails" in an ordinary PR become so debased that no further data in the PR deserves to be eligible to become skeptically surmised, and perhaps worthy of the more painstaking effort to scientifically probe that data’s uh "significance"? The added evaluated comment, the absence of side effects of this drug (NX-1207) would be stunningly novel. Even if the results of the data, merely could be “proven” to be equal to current remedies for over 100 million afflicted men, that drug might be a billion dollar + drug.

http://biz.yahoo.com/bw/080220/20080220005851.html?.v=1